For fiscal 2026 (ended Jun 30, 2026), Mesoblast Limited reported $120.25M of revenue and -$57.50M of net income.
MESO revenue was $120.25M for fiscal 2026 (ended Jun 30, 2026), up 599.2% from fiscal 2025. Compound annual growth was +74.5% over 5 years and +10.9% over 10 years. It rose in 5 of the last 10 fiscal years. Fiscal 2026 is the highest of the 11 fiscal years on file.
MESO net income was -$57.50M for fiscal 2026 (ended Jun 30, 2026), compared with -$102.14M in fiscal 2025.
MESO diluted EPS was -$0.04 for fiscal 2026 (ended Jun 30, 2026), compared with -$0.08 in fiscal 2025.
MESO free cash flow was -$44.66M for fiscal 2026 (ended Jun 30, 2026), compared with -$50.63M in fiscal 2025.
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $120.25M | $17.20M | $5.90M | $7.50M | $10.21M | $7.43M | $32.16M | $16.72M | $17.34M | $2.41M |
| Cost of revenue | $16.67M | $5.13M | $0 | $0 | - | - | - | - | - | - |
| Gross profit | $103.58M | $12.07M | $5.90M | $7.50M | - | - | - | - | - | - |
| Research and development | $97.51M | $34.81M | $39.72M | $52.82M | $32.81M | $53.01M | $56.19M | $59.81M | $65.93M | $58.91M |
| Selling, general and admin | $57.35M | $39.31M | $24.98M | $27.48M | - | - | - | - | - | - |
| Interest expense | $19.87M | $21.75M | $20.66M | $19.44M | $16.91M | $15.94M | $14.72M | $11.70M | $1.83M | - |
| Pre-tax income | -$56.89M | -$101.81M | -$88.15M | -$82.10M | -$91.59M | -$99.63M | -$87.36M | -$98.75M | -$65.98M | -$90.22M |
| Income tax | $613.0K | $330.0K | -$191.0K | -$212.0K | -$239.0K | -$819.0K | -$9.41M | -$8.96M | -$30.69M | -$13.40M |
| Net income | -$57.50M | -$102.14M | -$87.96M | -$81.89M | -$91.35M | -$98.81M | -$77.94M | -$89.80M | -$35.29M | -$76.81M |
| EPS, basic | -$0.04 | -$0.08 | -$0.09 | -$0.11 | -$0.13 | -$0.16 | -$0.15 | -$0.18 | -$0.08 | -$0.19 |
| EPS, diluted | -$0.04 | -$0.08 | -$0.09 | -$0.11 | -$0.13 | -$0.16 | -$0.15 | -$0.18 | -$0.08 | -$0.19 |
| Diluted shares | 1.29B | 1.21B | 986.7M | 777.7M | 682.9M | 605.1M | 528.8M | 494.4M | 465.7M | 399.0M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $102.91M | $161.55M | $62.96M | $71.32M | $60.45M | $136.88M | $129.33M | $50.43M | $37.76M | $45.76M |
| Receivables | $57.66M | $14.87M | $20.95M | $7.00M | $4.40M | $4.84M | $1.57M | $4.06M | $50.37M | $3.74M |
| Inventory | $28.11M | $22.25M | $0 | - | - | - | - | - | - | - |
| Current assets | $197.49M | $204.35M | $86.46M | $81.66M | $69.84M | $148.23M | $136.55M | $62.52M | $101.07M | $63.61M |
| Total assets | $773.08M | $784.68M | $669.15M | $669.41M | $662.14M | $744.72M | $733.60M | $652.12M | $692.44M | $655.69M |
| Current liabilities | $81.11M | $102.63M | $73.24M | $41.98M | $51.37M | $94.27M | $90.14M | $44.33M | $24.00M | $36.67M |
| Short-term debt | - | - | - | - | $5.02M | $53.20M | - | - | - | - |
| Long-term debt | $108.64M | $67.74M | $100.48M | $102.81M | $91.62M | $41.05M | $57.02M | $67.28M | $59.40M | - |
| Total debt | $108.64M | $67.74M | $100.48M | $102.81M | $96.63M | $94.25M | $57.02M | $67.28M | $59.40M | $0 |
| Total liabilities | $204.67M | $187.24M | $188.80M | $167.58M | $165.10M | $163.32M | $184.28M | $171.06M | $146.44M | $138.92M |
| Shareholders' equity | $568.40M | $597.44M | $480.36M | $501.84M | $497.04M | $581.40M | $549.33M | $481.05M | $546.01M | $516.77M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.83M | -$49.95M | -$48.46M | -$63.27M | -$65.78M | -$100.75M | -$50.42M | -$57.79M | -$75.01M | -$95.47M |
| Capital expenditures | $833.0K | $680.0K | $271.0K | $264.0K | - | - | - | - | - | - |
| Free cash flow | -$44.66M | -$50.63M | -$48.73M | -$63.53M | - | - | - | - | - | - |
| Investing cash flow | -$1.02M | $120.0K | -$97.0K | -$194.0K | -$232.0K | -$1.65M | -$3.27M | -$1.00M | -$1.15M | $142.0K |
| Financing cash flow | -$15.33M | $147.34M | $40.25M | $74.50M | -$9.87M | $108.53M | $131.10M | $71.61M | $68.61M | $60.01M |
| Stock-based compensation | $14.87M | $22.09M | $5.87M | $3.65M | $5.54M | $12.51M | $7.52M | $4.37M | $6.20M | $5.28M |
| Depreciation and amortization | $8.59M | $6.40M | $4.67M | $4.11M | $4.38M | $4.26M | $3.67M | $2.14M | $2.65M | $3.06M |
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 599.2% | 191.4% | -21.3% | -26.5% | 37.4% | -76.9% | 92.3% | -3.6% | 618.9% | -94.3% |
| Gross margin | 86.1% | 70.2% | 100.0% | 100.0% | - | - | - | - | - | - |
| Net margin | -47.8% | -593.9% | -1490.3% | -1091.7% | -894.6% | -1329.2% | -242.4% | -537.0% | -203.5% | -3184.7% |
| Free cash flow margin | -37.1% | -294.4% | -825.6% | -847.0% | - | - | - | - | - | - |
| Return on equity | -10.1% | -17.1% | -18.3% | -16.3% | -18.4% | -17.0% | -14.2% | -18.7% | -6.5% | -14.9% |
| Return on assets | -7.4% | -13.0% | -13.1% | -12.2% | -13.8% | -13.3% | -10.6% | -13.8% | -5.1% | -11.7% |
| Current ratio | 2.43 | 1.99 | 1.18 | 1.95 | 1.36 | 1.57 | 1.51 | 1.41 | 4.21 | 1.73 |
| Debt to equity | 0.19 | 0.11 | 0.21 | 0.20 | 0.19 | 0.16 | 0.10 | 0.14 | 0.11 | 0.00 |
Source: XBRL data Mesoblast Limited files with the SEC, latest filing dated Aug 27, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MESO | $120.25M | +599.2% | -$57.50M | -47.8% | $1.88B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |